Smothering dystonia in a patient with oromandibular dystonia

Movement Disorders

Volumn 19, Issue 11, 2004, Pages 1374-1375

  Grill, Stephen ^a,b  

^a Movement Disorders Clinic   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Oromandibular dystonia; Striatonigral degeneration; Syncope

Indexed keywords

BOTULINUM TOXIN A; CARBIDOPA PLUS LEVODOPA; LEVODOPA; PERGOLIDE; SELEGILINE;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; CASE REPORT; DISEASE COURSE; DRUG WITHDRAWAL; DYSTONIA; FEMALE; HUMAN; JAW DISEASE; MOUTH DISEASE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION; SYMPTOMATOLOGY; SYNCOPE;

AIRWAY OBSTRUCTION; BOTULINUM TOXIN TYPE A; DIAGNOSIS, DIFFERENTIAL; DYSTONIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MANDIBULAR DISEASES; MASSETER MUSCLE; MEIGE SYNDROME; MIDDLE AGED; NEUROLOGIC EXAMINATION; SYNCOPE; TEMPORAL MUSCLE; TORTICOLLIS;

EID: 8844234255     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20203     Document Type: Article

References (5)

1. Watts RL, Brewer RP, Schneider JA, Mirra S. Corticobasal degeneration. In: Watts RL, Koller WC, editors. Movement disorders: neurologic principles and practice. New York: McGraw Hill; 1997. p 611-621.
2. Tan EK, Chan LL, Wong MC. Levodopa-induced oromandibular dystonia in progressive supranuclear palsy. Clin Neurol Neurosurg 2003;105:132-134.
3. Hamzei F, Rijntjes M, Gbadamosi J, Fuchs K, Weiller C, Münchau A. Life-threatening respiratory failure due to cranial dystonia after dental procedure in a patient with multiple system atrophy. Mov Disord 2003;18:959-961.
4. Bhattacharyya N, Tarsy D. Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia. Arch Otolaryngol Head Neck Surg 2001;127:389-392.
5. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 1999;53:2102-2107.